Trikafta is Vertex Pharmaceuticals' triple-combination CFTR modulator, pairing elexacaftor, tezacaftor, and ivacaftor tablets with a separate ivacaftor tablet. It is FDA-approved for people with cystic fibrosis age 2 and older who have at least one F508del mutation or another responsive mutation in the CFTR gene, which covers roughly 90 percent of the estimated 40,000 people living with cystic fibrosis in the United States. Trikafta does not cure cystic fibrosis, but clinical trials showed large improvements in lung function and quality of life, which is why Vertex has priced it as an orphan drug for a rare, life-shortening genetic disease.
Vertex set Trikafta's US list price near $370,000 per year in 2026, up from about $322,000 at its 2019 launch, following annual wholesale acquisition cost increases typical of specialty drugs. That works out to roughly $30,800 for a 28-day supply. Trikafta is not stocked at retail chains like a generic; it is dispensed almost exclusively through a small network of specialty pharmacies coordinated by Vertex GPS, so the cash price barely varies by location. What patients actually pay depends heavily on insurance type: commercial plans usually route to a $0 copay card, Medicare Part D caps annual out-of-pocket cost at $2,100 in 2026, and Medicaid copays are nominal.
The Inflation Reduction Act of 2022 created Medicare's Drug Price Negotiation Program, but Trikafta does not appear on the first 10-drug list (Maximum Fair Prices effective January 1, 2026) or the second 15-drug list (effective 2027). That is because the law exempts drugs whose only approved use treats a single rare disease, known as the orphan drug exclusion, and a 2025 amendment broadened that protection further. Cystic fibrosis patients relying on Medicare Part D should still confirm their plan's formulary tier and check the Medicaid income limits if they might qualify for dual coverage, since Medicaid can pick up cost-sharing that Part D leaves behind.
What Trikafta Costs by Point of Pay (2026)
The price you pay depends almost entirely on WHERE you pay. The same trikafta can cost many times more at a hospital than at your local pharmacy:
2026 Trikafta Price by Point of Pay| Where you pay | Typical cost | Notes |
|---|
| Specialty pharmacy (cash, no insurance) | $29,500 - $31,500/month (28-day supply) | List price in 2026; specialty pharmacies rarely discount from wholesale acquisition cost |
| Medicare Part D (2026) | $0 - $2,100/year total across all Part D drugs | Trikafta is a specialty formulary tier drug; coinsurance applies until you hit the annual cap |
| Commercial insurance | $0/fill with Vertex GPS copay card (up to $20,000/year) | Prior authorization and CFTR genetic mutation confirmation required |
| Vertex GPS Patient Assistance Program | $0/month for eligible uninsured patients | Not available to patients with Medicare, Medicaid, TRICARE, or VA coverage |
| Medicaid | $1 - $10/prescription, with prior authorization | Covered nationwide for confirmed cystic fibrosis; nominal copay per state rules |
Cash list price reflects 2026 wholesale acquisition cost reporting. Most insured patients never pay the list price; the real cost driver is which assistance program you qualify for.
Source: Vertex Pharmaceuticals pricing disclosures, CMS Medicare Part D 2026 benefit parameters, Vertex GPS program terms
Why Hospitals Charge So Much
Trikafta almost never appears as a fresh charge on a hospital bill because cystic fibrosis patients fill it through Vertex GPS's specialty pharmacy network for home use, not through a hospital pharmacy. When a patient is admitted for a pulmonary exacerbation, most hospitals allow the patient to continue their own home supply. If the hospital pharmacy does have to dispense a replacement supply during a longer inpatient stay, the charge appears as a specialty pharmacy line item with facility handling fees, nursing administration charges, and overhead layered on top of the roughly $30,800 monthly list price.
Vertex Pharmaceuticals sets the list price nationally, so the underlying drug cost does not vary by hospital the way a procedure might. What varies is the facility markup layered on top. If an inpatient itemized bill shows Trikafta at $45,000 or more for a single month, ask for the National Drug Code and compare it against the manufacturer's published wholesale acquisition cost. Facility markups above roughly $95,000 per month-equivalent supply are common targets for a billing dispute, especially when the hospital never coordinated with Vertex GPS to bill the patient's existing assistance program.
Patient Assistance Programs
Vertex Pharmaceuticals runs the Vertex GPS (Guidance and Patient Support) program, which is the primary way patients avoid Trikafta's roughly $370,000 annual list price. A separate nonprofit, the HealthWell Foundation, funds a cystic fibrosis treatment fund that many patients layer on top of manufacturer support for remaining cost-sharing.
Patient assistance programs for Trikafta| Manufacturer program | Cost / Benefit | How to apply |
|---|
| Vertex GPS Co-pay Assistance Program | $0 per fill for commercially insured patients, up to $20,000 per year | vertexgps.com/financial-assistance |
| Vertex GPS Patient Assistance Program | Free Trikafta for eligible uninsured or underinsured patients, reviewed case by case | vertexgps.com/financial-assistance |
| HealthWell Foundation Cystic Fibrosis Treatments Fund | Grants toward copays, coinsurance, and deductibles for households at or below 500% FPL | healthwellfoundation.org/fund/cystic-fibrosis-treatments-2 |
| NeedyMeds Drug Discount Card | Variable discount at participating pharmacies for those who do not qualify elsewhere | needymeds.org |
Manufacturer copay cards, including the Vertex GPS Co-pay Assistance Program, cannot be used by anyone enrolled in Medicare, Medicaid, TRICARE, or VA benefits under the federal anti-kickback statute (42 U.S.C. Section 1320a-7b). If you have government insurance, apply for the Vertex GPS free-medicine track or a third-party foundation like HealthWell instead, since those are not manufacturer coupons.
Source: Vertex GPS program terms, HealthWell Foundation Cystic Fibrosis Treatments Fund, NeedyMeds.org
Medicare Part D
Trikafta is a Medicare Part D drug placed on the specialty tier of nearly every formulary because it costs more than $30,800 per month at list price. In 2026, your total annual out-of-pocket spending across all Part D drugs combined is capped at $2,100 thanks to the Inflation Reduction Act, which replaced the old catastrophic-phase coinsurance. Once you hit $2,100 in a calendar year, you pay $0 for the rest of the year on covered drugs, including Trikafta.
Medicare Advantage and standalone Part D plans require prior authorization for Trikafta, typically confirming a cystic fibrosis diagnosis, at least one eligible CFTR mutation via genetic testing, and prescribing by or in consultation with a CF specialist. Because Trikafta has no generic equivalent and treats a rare, progressive disease, appeals for coverage denials are usually successful when the mutation and diagnosis documentation is complete. Beneficiaries with limited income can also apply for the Medicare Extra Help low-income subsidy, which lowers Part D premiums and cost-sharing well below the standard 2026 amounts.
The Medicare Prescription Payment Plan, available since 2025, lets you spread your Part D out-of-pocket costs evenly across the calendar year instead of hitting the $2,100 cap in a single month. Given Trikafta's cost, many patients could reach the annual cap with their very first fill of the year; ask your Part D plan to enroll you in this payment plan if a large upfront bill would create hardship.
Common Trikafta Billing Errors
If you or your CF care center received a bill for Trikafta above $10 on Medicaid, above the $2,100 annual Part D cap on Medicare, or any amount at all with an active Vertex GPS copay card on commercial insurance, check for these issues before paying:
- Prior authorization not submitted or lapsed at renewal. Most plans require annual reauthorization with updated genetic mutation and diagnosis documentation.
- Vertex GPS copay card not applied at the specialty pharmacy despite active enrollment. Ask the specialty pharmacy to rerun the claim with the copay assistance BIN/PCN before paying cash.
- AM and PM tablet packs billed as two separate fills, doubling the copay. Trikafta ships as a single 28-day carton containing both the morning triple-combination tablet and the evening ivacaftor tablet; it should be billed as one fill.
- Charged coinsurance after already hitting the $2,100 Part D out-of-pocket cap for the year on Medicare.
- Cash price charged to a patient who qualifies for the Vertex GPS free-medicine program but whose enrollment paperwork stalled between the CF care center and Vertex GPS.
- Inpatient hospital charge for a continued Trikafta supply marked up several times the roughly $30,800 monthly list price without the hospital coordinating with Vertex GPS billing.
Frequently Asked Questions
How much does Trikafta cost without insurance in 2026?
Trikafta's cash list price in 2026 is about $29,500 to $31,500 for a 28-day supply, or roughly $370,000 per year. Trikafta is dispensed almost exclusively through specialty pharmacies, so the cash price barely varies by location. Uninsured patients rarely pay this price directly; most qualify for the Vertex GPS patient assistance program, which can supply Trikafta free of charge after a benefits and income review.
Is there a generic version of Trikafta?
No. As of 2026, there is no FDA-approved generic for Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor). Vertex's patents are expected to run through roughly 2037, with an estimated generic launch date around 2038. A lower-cost generic made by Beximco Pharmaceuticals is sold in some other countries but is not FDA-approved for the US market. Trikafta is a small-molecule drug, not a biologic, so it does not have a biosimilar pathway.
How do I apply for the Vertex GPS patient assistance program?
Call Vertex GPS at 1-877-752-5933 (option 2) or visit vertexgps.com/financial-assistance. Your CF care team completes an enrollment and consent form with your prescription and CFTR mutation report, then faxes it to Vertex GPS at 1-888-952-5933. A case manager reviews your insurance status; commercially insured patients get an automatic $0 copay, while uninsured patients submit income proof for the free-medicine track. Processing typically takes about a week, and enrollment must be renewed annually.
Can I use the Vertex GPS copay card with Medicare?
No. Federal anti-kickback law bars manufacturer copay cards, including the Vertex GPS Co-pay Assistance Program, from being used by anyone with Medicare, Medicaid, TRICARE, or VA benefits. If you have government insurance, apply for the Vertex GPS free-medicine track instead, or for the HealthWell Foundation Cystic Fibrosis Treatments Fund, which is a third-party charity and not restricted the same way.
What if my insurance denies coverage for Trikafta?
Request the written denial letter, then have your CF care center file an internal appeal with your CFTR genetic mutation report, current lung function data, and CF diagnosis. Ask for a peer-to-peer review between your pulmonologist and the plan's medical director. If denied again, file for external review through your state Department of Insurance within about four months. While you appeal, ask about the Vertex GPS bridge program, which can supply Trikafta free on a temporary basis.
Does the IRA negotiated Maximum Fair Price apply to Trikafta?
No. Trikafta is exempt from the Inflation Reduction Act's Medicare Drug Price Negotiation Program under the orphan drug exclusion, because cystic fibrosis is its only FDA-approved indication. It does not appear on the 10-drug list effective January 1, 2026, or the 15-drug list effective 2027. A 2025 amendment further broadened this exemption, so there is no negotiated Maximum Fair Price to compare against the roughly $370,000 annual list price.
Does Medicare cover Trikafta, and what is the 2026 out-of-pocket cap?
Yes, Medicare Part D covers Trikafta for confirmed cystic fibrosis with an eligible CFTR mutation, subject to prior authorization. Your total out-of-pocket spending across all Part D drugs combined is capped at $2,100 for 2026 under the Inflation Reduction Act. Given Trikafta's cost, many Medicare patients reach that cap with their first fill of the year, after which covered drugs cost $0 for the rest of the year.
What is the difference between Trikafta and Alyftrek?
Both are Vertex CFTR modulators for cystic fibrosis, but they are different drugs, not brand names of the same product. Trikafta combines elexacaftor, tezacaftor, and ivacaftor with a separate morning and evening tablet regimen. Alyftrek (vanzacaftor/tezacaftor/deutivacaftor), approved more recently, is a once-daily single tablet designed to eventually replace Trikafta for many eligible patients. Alyftrek is not a generic or biosimilar of Trikafta; it carries its own list price and its own Vertex GPS enrollment.
